We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 52.00 | 3,300 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 51.00 | 53.00 | 52.00 | 52.00 | 52.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 12.61M | -409k | -0.0117 | -44.44 | 18.12M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 09:18:20 | O | 500 | 53.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/4/2024 | 14:07 | ALNC |  Cambridge Cognition partly-owned spin-off gets GBP1.5 million funding |
| 23/4/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC COG spin-out Monument Therapeutics.. |
| 02/4/2024 | 16:20 | UK RNS | Cambridge Cognition Holdings PLC Total Voting Rights and Block Listing.. |
| 21/3/2024 | 14:33 | ALNC | EARNINGS AND TRADING: Hostelworld boosts revenue and narrows loss |
| 21/3/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC Formation of new Scientific Advisory Board |
| 21/2/2024 | 14:33 | ALNC | EARNINGS AND TRADING: Chamberlin loss narrows; Corero inks Latam deal |
| 21/2/2024 | 10:16 | UK RNS | Cambridge Cognition Holdings PLC Holding(s) in Company |
| 21/2/2024 | 07:00 | UK RNS | Cambridge Cognition Holdings PLC Cambridge Cognition and ActiGraph.. |
| 30/1/2024 | 16:20 | UK RNS | Cambridge Cognition Holdings PLC Director/PDMR Share Purchases |
| 30/1/2024 | 12:27 | ALNC | TRADING UPDATES: Synthomer predicts revenue decline amid challenges |
Cambridge Cognition (COG) Share Charts1 Year Cambridge Cognition Chart |
|
1 Month Cambridge Cognition Chart |
Intraday Cambridge Cognition Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/4/2024 | 09:14 | Cambridge Cognition Holdings (COG) | 599 |
| 02/2/2023 | 20:18 | Dementia - Computerised Neuropsychological Testing | 189 |
| 30/4/2019 | 22:22 | Cambridge Cognition at UK Investor Show | 1 |
| 02/9/2017 | 15:05 | COG with Charts & News | 63 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:18:21 | 53.00 | 500 | 265.00 | O |
| 07:49:01 | 51.62 | 2,800 | 1,445.36 | O |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by Cambridge Cognition Daily Update Cambridge Cognition Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker COG. The last closing price for Cambridge Cognition was 52p.Cambridge Cognition currently has 34,852,833 shares in issue. The market capitalisation of Cambridge Cognition is £18,123,473. Cambridge Cognition has a price to earnings ratio (PE ratio) of -44.44. This morning COG shares opened at 52p |
Posted at 23/4/2024 08:02 by earwacks Excellent summary again Fathom. It occurred to me that Monument could end up having a higher market cap than Cog at some stage. They did say they had some exciting news at the beginning of the year. I guess this is it! |
Posted at 23/4/2024 07:27 by 40 fathoms Today's RNS confirms the Cambridge Cognitions equity in Monument Therapeutics is valued at @2.5 million based on the closed funding round. This compares to a carrying value of GBP65k. In addition the 12.5% top line gross royalty is worth considerably more than the equity. So at the mark from this recent funding round the value of Monument Therapeutics to Cambridge Cognition is in excess of 5 million. Should this or Monument's other drug enter phase II trials the total value will be significantly more than the current COG market cap.Monument Therapeutics strategy is out-license Phase II drug development. So its possible, with a favorable outcome in this proof of mechanism trial, that in the next 12 months a deal could be reached with Pharma. It is probably worth pointing out that Monument Therapeutics is not developing new drugs, its reformulating generic drugs and paring them with a digital biomarker to ensure they get to patients in which they will work. This should remove safety related risk from the clinical trials as these well known and widely used APIs. |
Posted at 04/3/2024 12:01 by earwacks I have the occasional look in as he does sometimes conduct a good interview, nBut his doctor like prognosis on chart reading is quite ridiculous, particularly on illiquid small caps that seem more inappropriate than bigger market cap stock. I did follow Alpesh Patel (ex barrister/stock analyst). He used charts more for momentum investing, which I kind of get, but still find it pretty micky mouse investing. Paul Scot says he has been approached by the board of Cog for an interview. Paul is interested in Cog to a degree but has been a bit wary of late. Seems to be getting slightly more interested again. I expect you are correct about sudden moves. Brett Gordon has increased his stake twice recently without much impact. I think it must have been an overhang from director sells in the acquired companies. Normally his buys would have pushed the stock right back up. |
Posted at 26/2/2024 19:10 by bedford1976 What is baffling me today is apparently 716k shares have been traded. I monitor this share most days and it normally trades 7k - 35k on a regular basis. Seems a huge spike in trading but unfortunately no upward movement in the share price. Quite a disappointing day really. |
Posted at 26/2/2024 11:53 by purplepelmets ew, i would add too, but so teed off about that aquisition which meant we would be running at a loss for years more instead of running at a profit already. did not seem significant or neccessary to scupper the share price like that. cant forgive Storky for this |
Posted at 26/2/2024 10:07 by bedford1976 To be honest the share price hasn't gone up very much considering the Midas tip yesterday.Obviously Sunday paper share tips do do generate as much investor interest as you would think. |
Posted at 21/2/2024 12:09 by earwacks Brett Gordon added another .8 percent taking his holding to over 7 per cent.would be kicking myself if I missed out completely on this price. Seems like there maybe some overhang still if .8 percent cant shift the share price Have to think seriously about making some more funds available. Dont really like the doldrum state of the market so far this year, but encouraging to see stocks like cmcx recover and my broker Jarvis come to that! Gl all |
Posted at 13/10/2023 04:42 by 40 fathoms This link is to an investor day video that was posted today by Cogstate to help investors understand the their cognitive digital trials business. The video is long, so it might something for the weekend viewing.Cogstate is a very similar company to CAMCOG. However, it is further advanced in its commercial development and has a much narrower focus, primarily on Alzheimer's (@70% of revenue) and rare diseases (@10% of revenue). At this point the companies are rarely in direct competition and for both of them their biggest competitors remain the providers of traditional pencil and paper tests. Just to give a sense of the potential size and scope of these markets last year Cogstate put out an estimate that despite being far in the lead in AD they still only had @17% of cognitive testing in the AD trials market. It is also worth noting that CAMCOG is involved with numerous early stage AD trials and will end up with a decent share of the AD market overtime. The video gives a very good overview of the cognitive testing business case and also the huge and deep moat that these companies are able to enjoy. It also shows very clearly how well CAMCOG is positioned in the cognitive trial services ecosystem. CAMCOG is far ahead, both in terms of its technology and the scope of services it is able to offer in to trials. It is also probably also worth mentioning that AD only represents about 15% of the total spend in CNS space. I hold both companies and it is clear that both will grow revenue significantly in the coming 3 or 4 years. However, for CAMCOG specifically we should understand it is about 3 or 4 years behind Cogstate in its move from R&D and validation to commercialisation. Cogstate clearly demonstrates the commercial path and revenue trajectory that we are on. |
Posted at 25/2/2023 10:05 by 40 fathoms Situation is interesting at Cogstate, it is clear that Martin Myer is prepared to sell. With that Cogstate will not last more than 18 months as a listed company and that will see interest quickly turn to Cambridge Cognition. It is also certain that he will not let the business go cheaply, he certainly does not need the money as he is part of the Myer Department Stores family dynasty. I assume this might be why the talks broke down, it is also clear that last week the possibility of a takeover leaked given the huge sure in volumes. Anyway, if and when they sell at a great price it will be fantastically supportive for Cambridge Cognitions share price, as its business is much higher margin, its technology is much more sensitive and it has a much wider therapeutic area focus.The read across for Cambridge Cognition on the profit warning was limited. The warning relates mainly to a slower than expected enrolment at a very large Phase III AD trial being conducted by Eli Lilly. When I say large trial the contracted amount is something like a $ 28 million over 3 years and they are right in the meat of it at the moement. Their test is being used as an endpoint. Overtime what constitutes a large contract for Cambridge Cognition will rise considerably. Currently $ 2-3 million is the upper range of what we sign. As we start to see more large neurodegenerative Phase III trials and offer a full range of service we will see contracts in excess of $10 million. All of the forward looking metrics Cogstate gave were positive, both book to bill and cash inflow. They will report full details next Tuesday. |
Posted at 07/1/2023 09:32 by 40 fathoms Yesterday evening Eisai/Biogen recived accelerated FDA approval for Lecenamab, which will now be renamed as Leqembi. This is a drug that will be used to treat early stage Alzheimers and although it is far from perfect this is a pivotal moment along the path to changing the treatment paradigm in AD.The follow on effects for Cambridge Cognition over the next decade will be significant and twofold. Firstly, you will see a significant number of new AD clinical trials initiated, both for new APIs targeting beta amyloid and also targeting new mechanisms of action. In addition you will start to see trials of drug combinations. Leqembi and Donepezil would be an obvious one, given that Aricept is also an Eisai drug. A share of all this additional work will come to Cambridge Cognition. Secondly, now that we have the ability to modify the disease, faster and earlier diagnosis of AD is going to be crucial. It will not be affordable, nor practicable to definitively test everyone (PET scan or lumbar puncture) who turns up in the GP clinic saying they forgot where they left the car in the carpark last week or they could not remember the name of their postman. The answer is a quick, cheap and accurate digital test that will determine if your cognition is normal, both against your peer group but also against yourself when tested longitudinally. There are only two companies that are in a position to provide widely validated, highly sensitive, digital administered tests and Cambridge Cognition is one of these companies. Over the next decade, globally. Tests in this health screening market should be somewhere between 5 million & 50 million annually, multiply this number by @ $10-$12 per test (this is an estimate of what Cogstate will receive via its licensing agreement with Eisai) and then assign a percentage of the resultant figure to Cambridge Cognition. If we take 5 million tests per year and US$ 10 dollars per test and assign a 10% market share to Cambridge Cognition that would be US$ 5 million dollars in annual revenue and note that revenue has 95%+ gross margin. If we keep Cambridge's share of the market at 10% but increase the $ per test to $12 and estimating a market of 30 million tests per year. We would see a COG revenue of $36 million per year. Just for a little bit more context as to how this market might evolve you might look at what Eisai and Cogstate are starting to do in Japan. In Japan it is mandatory for an employer to offer an annual health check, known as kenko shindan. Eisai is working on having their Cognigram tests included for all over 50s. They are starting to also have them embedded in private health insurance physicals and they are also exploring with the government making them a part of the driving licence renewal process, after a certain age. The other factor to consider is that once you are on some form of treatment you will be tested regularly to make sure the drug is having a positive effect. Last but not least Eli Lilly will be filling with the FDA before the end of 2023 for approval of their beta amyloid clearing therapy known as daonanemab. Should this be approved this will reinforce all of the factors highlighted above.. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
